Comment
. 2008 Oct 1;26(28):4693-4; author reply 4694-5.
doi: 10.1200/JCO.2008.18.8060.
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm
- PMID: 18824719
- DOI: 10.1200/JCO.2008.18.8060
Item in Clipboard
Comment
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm
J Clin Oncol.
.
No abstract available
Comment on
-
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898. J Clin Oncol. 2008. PMID: 18421053 Clinical Trial.
Similar articles
-
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.Clin Colorectal Cancer. 2008 Jul;7(4):226. doi: 10.3816/CCC.2008.n.030. Clin Colorectal Cancer. 2008. PMID: 18650190 No abstract available.
-
[Metastatic colorectal cancer: adjournments from ESMO 2006].Tumori. 2006 Nov-Dec;92(6):1-12. doi: 10.1177/030089160609200627. Tumori. 2006. PMID: 17262903 Italian. No abstract available.
-
Current role of bevacizumab in colorectal cancer.Clin Adv Hematol Oncol. 2009 Jun;7(6):375-6. Clin Adv Hematol Oncol. 2009. PMID: 19606071 No abstract available.
-
Common side effects and interactions of colorectal cancer therapeutic agents.J Pract Nurs. 2011 Spring;61(1):7-20. J Pract Nurs. 2011. PMID: 21751717 Review. No abstract available.
-
Update on capecitabine alone and in combination regimens in colorectal cancer patients.Cancer Treat Rev. 2010 Nov;36 Suppl 3:S46-55. doi: 10.1016/S0305-7372(10)70020-7. Cancer Treat Rev. 2010. PMID: 21129610 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
